MA39219B1 - Nouveaux composés inhibiteurs de la kinase lrrk2 utilisés pour le traitement du parkinson, de l’alzheimer et de la sclérose latérale amyotrophique - Google Patents
Nouveaux composés inhibiteurs de la kinase lrrk2 utilisés pour le traitement du parkinson, de l’alzheimer et de la sclérose latérale amyotrophiqueInfo
- Publication number
- MA39219B1 MA39219B1 MA39219A MA39219A MA39219B1 MA 39219 B1 MA39219 B1 MA 39219B1 MA 39219 A MA39219 A MA 39219A MA 39219 A MA39219 A MA 39219A MA 39219 B1 MA39219 B1 MA 39219B1
- Authority
- MA
- Morocco
- Prior art keywords
- alzheimer
- lateral sclerosis
- amyotrophic lateral
- lrrk2 kinase
- new
- Prior art date
Links
- 208000024827 Alzheimer disease Diseases 0.000 title abstract 2
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 title abstract 2
- WCIGMFCFPXZRMQ-UHFFFAOYSA-N 5-(2-fluoropyridin-4-yl)-2-phenylmethoxy-n-pyridin-3-ylbenzamide Chemical class C1=NC(F)=CC(C=2C=C(C(OCC=3C=CC=CC=3)=CC=2)C(=O)NC=2C=NC=CC=2)=C1 WCIGMFCFPXZRMQ-UHFFFAOYSA-N 0.000 title 1
- 208000018737 Parkinson disease Diseases 0.000 abstract 1
- 108091000080 Phosphotransferase Proteins 0.000 abstract 1
- 102000001253 Protein Kinase Human genes 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000006806 disease prevention Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 102000020233 phosphotransferase Human genes 0.000 abstract 1
- 108060006633 protein kinase Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Psychology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2014000139 | 2014-01-29 | ||
| PCT/CN2015/000055 WO2015113452A1 (en) | 2014-01-29 | 2015-01-28 | Compounds |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MA39219A1 MA39219A1 (fr) | 2017-09-29 |
| MA39219B1 true MA39219B1 (fr) | 2018-11-30 |
Family
ID=53756224
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA39219A MA39219B1 (fr) | 2014-01-29 | 2015-01-28 | Nouveaux composés inhibiteurs de la kinase lrrk2 utilisés pour le traitement du parkinson, de l’alzheimer et de la sclérose latérale amyotrophique |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US10087186B2 (enExample) |
| EP (1) | EP3099695B1 (enExample) |
| JP (1) | JP6422986B2 (enExample) |
| KR (1) | KR20160106622A (enExample) |
| CN (1) | CN105940004B (enExample) |
| AU (2) | AU2015210593A1 (enExample) |
| CA (1) | CA2937431A1 (enExample) |
| CL (1) | CL2016001895A1 (enExample) |
| CR (1) | CR20160348A (enExample) |
| DO (2) | DOP2016000195A (enExample) |
| EA (1) | EA029774B1 (enExample) |
| ES (1) | ES2802174T3 (enExample) |
| IL (1) | IL246579B (enExample) |
| MA (1) | MA39219B1 (enExample) |
| MX (1) | MX367370B (enExample) |
| PE (1) | PE20161443A1 (enExample) |
| PH (1) | PH12016501307A1 (enExample) |
| SG (1) | SG11201605342UA (enExample) |
| UA (1) | UA118369C2 (enExample) |
| WO (1) | WO2015113452A1 (enExample) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10339791B2 (en) | 2007-06-12 | 2019-07-02 | Icontrol Networks, Inc. | Security network integrated with premise security system |
| WO2017156493A1 (en) | 2016-03-11 | 2017-09-14 | Denali Therapeutics Inc. | Compounds, compositions, and methods |
| PE20161443A1 (es) | 2014-01-29 | 2017-01-06 | Glaxosmithkline Ip Dev Ltd | Compuestos |
| US9815841B2 (en) | 2014-01-29 | 2017-11-14 | Glaxosmithkline Intellectual Property Development Limited | Compounds |
| CN105153131B (zh) * | 2015-09-21 | 2017-10-17 | 马彦丽 | 一种在护理上治疗人神经胶质瘤的药物组合物 |
| CN105348270B (zh) * | 2015-11-09 | 2018-01-09 | 吕显艳 | 一种防治牙体牙髓感染的药物组合物 |
| US11214565B2 (en) | 2015-11-20 | 2022-01-04 | Denali Therapeutics Inc. | Compound, compositions, and methods |
| JP2018537502A (ja) | 2015-12-16 | 2018-12-20 | サウザーン リサーチ インスチチュート | ピロロピリミジン化合物、キナーゼｌｒｒｋ２阻害剤としての使用、及びその調製方法 |
| CN105418616B (zh) * | 2015-12-26 | 2018-01-12 | 山东大学 | 一种含有 4‑氨基吡唑结构的jak 激酶抑制剂及其制备方法和应用 |
| PT3472153T (pt) | 2016-06-16 | 2021-12-31 | Denali Therapeutics Inc | Pirimidin-2-ilamino-1h-pirazóis como inibidores de lrrk2 para uso no tratamento de distúrbios neurodegenerativos |
| JP2020505398A (ja) * | 2017-01-25 | 2020-02-20 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ | 化合物 |
| KR20180097162A (ko) * | 2017-02-22 | 2018-08-30 | 국립암센터 | 피롤로-피리미딘 유도체 화합물, 이의 제조방법 및 이를 유효성분으로 함유하는 단백질 키나아제 관련 질환의 예방 또는 치료용 약학적 조성물 |
| AU2018239798B2 (en) | 2017-03-23 | 2020-08-27 | Daegu Gyeongbuk Institute Of Science And Technology | Pyrrolo-pyridine derivative compound, method for preparing same, and pharmaceutical composition containing same as active ingredient for prevention or treatment of protein kinase-related diseases |
| SG11202005264PA (en) * | 2017-12-05 | 2020-07-29 | Oscotec Inc | Pyrrolo(pyrazolo)pyrimidine derivative as lrrk2 inhibitor |
| CN108715834B (zh) * | 2018-06-01 | 2021-09-14 | 天晴干细胞股份有限公司 | 一种富含cd41+、cd81+微囊的血小板裂解液制备方法 |
| WO2020036437A1 (ko) * | 2018-08-16 | 2020-02-20 | 재단법인 대구경북첨단의료산업진흥재단 | 치환된 헤테로아릴 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 단백질 키나아제 관련 질환의 예방 또는 치료용 약학적 조성물 |
| MX2021003516A (es) * | 2018-09-25 | 2021-05-27 | Cardurion Pharmaceuticals Llc | Compuesto de aminopirimidina. |
| CA3168211A1 (en) | 2019-01-18 | 2020-07-23 | Voronoi Co., Ltd. | Pyrrolopyridine derivative and use thereof for preventing or treating protein kinase related disease |
| CZ308800B6 (cs) * | 2019-02-12 | 2021-05-26 | Univerzita Palackého v Olomouci | Heterocyklické dusíkaté deriváty purinu, farmaceutické přípravky obsahující tyto deriváty a jejich použití při neuroprotekci |
| KR20230091150A (ko) * | 2020-10-29 | 2023-06-22 | 수저우 야바오 파마슈티걸 알앤디 컴퍼니 리미티드 | 치환된 디아릴아민 화합물 및 이의 약학적 조성물, 제조 방법과 용도 |
| KR20220081631A (ko) | 2020-12-09 | 2022-06-16 | 보로노이 주식회사 | 염증성 질환의 예방 및/또는 치료를 위한 피롤로-피리딘 유도체 화합물의 신규 용도 |
| WO2023073013A1 (en) | 2021-10-27 | 2023-05-04 | H. Lundbeck A/S | Lrrk2 inhibitors |
| WO2023076404A1 (en) | 2021-10-27 | 2023-05-04 | Aria Pharmaceuticals, Inc. | Methods for treating systemic lupus erythematosus |
| TW202412777A (zh) | 2022-09-15 | 2024-04-01 | 丹麥商Ｈ 朗德貝克公司 | 富白胺酸重複激酶2（lrrk2）抑制劑 |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005028480A2 (en) | 2003-09-03 | 2005-03-31 | Neurogen Corporation | 5-aryl-pyrazolo[4,3-d]pyrimidines, pyridines, and pyrazines and related compounds |
| GB0420719D0 (en) | 2004-09-17 | 2004-10-20 | Addex Pharmaceuticals Sa | Novel allosteric modulators |
| WO2006045392A2 (en) | 2004-10-21 | 2006-05-04 | GSF-Forschungszentrum für Umwelt und Gesundheit GmbH | Kaspp (lrrke) gene, its production and use for the detection and treatment of neurodegenerative disorders |
| WO2006050076A1 (en) | 2004-10-29 | 2006-05-11 | Janssen Pharmaceutica, N.V. | Pyrimidinyl substituted fused-pyrrolyl compounds useful in treating kinase disorders |
| NO323175B1 (no) | 2004-12-23 | 2007-01-15 | Jan O Aasly | Framgangsmate for a pavise en mutasjon som forarsaker arvelig parkinsonisme |
| WO2007042298A1 (en) | 2005-10-13 | 2007-04-19 | Glaxo Group Limited | Pyrrolopyrimidine derivatives as syk inhibitors |
| WO2007125405A2 (en) | 2006-05-01 | 2007-11-08 | Pfizer Products Inc. | Substituted 2-amino-fused heterocyclic compounds |
| WO2009036066A1 (en) | 2007-09-10 | 2009-03-19 | Curis, Inc. | Vegfr inhibitors containing a zinc binding moiety |
| US9315449B2 (en) | 2008-05-15 | 2016-04-19 | Duke University | Substituted pyrazoles as heat shock transcription factor activators |
| US8158636B2 (en) | 2008-05-19 | 2012-04-17 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
| WO2009143404A1 (en) | 2008-05-23 | 2009-11-26 | Wyeth | Piperazine metabotropic glutamate receptor 5 (mglur5) negative allosteric modulators for anxiety/depression |
| US9908884B2 (en) | 2009-05-05 | 2018-03-06 | Dana-Farber Cancer Institute, Inc. | EGFR inhibitors and methods of treating disorders |
| BR112012006859A2 (pt) * | 2009-09-29 | 2019-09-24 | Glaxo Group Ltd | compostos |
| WO2011153553A2 (en) | 2010-06-04 | 2011-12-08 | The Regents Of The University Of California | Methods and compositions for kinase inhibition |
| WO2012009258A2 (en) | 2010-07-13 | 2012-01-19 | Edward Roberts | Peptidomimetic galanin receptor modulators |
| WO2012045195A1 (en) | 2010-10-09 | 2012-04-12 | Abbott Laboratories | Pyrrolopyrimidines as fak and alk inhibiters for treatment of cancers and other diseases |
| CN103298474B (zh) | 2010-11-10 | 2016-06-29 | 无限药品股份有限公司 | 杂环化合物及其用途 |
| PH12013500880A1 (en) * | 2010-11-10 | 2013-07-01 | Hoffmann La Roche | Pyrazole aminopyrimidine derivatives as lrrk2 modulators |
| JP5937102B2 (ja) | 2010-12-14 | 2016-06-22 | エレクトロフォレティクス リミテッド | カゼインキナーゼ１デルタ（ｃｋ１デルタ）阻害剤 |
| CA2831634C (en) | 2011-04-21 | 2019-11-12 | Origenis Gmbh | Pyrazolo [4,3-d] pyrimidines useful as kinase inhibitors |
| AU2012311184A1 (en) | 2011-09-22 | 2014-03-06 | Pfizer Inc. | Pyrrolopyrimidine and purine derivatives |
| BR112014012822A8 (pt) * | 2011-11-30 | 2017-07-11 | Hoffmann La Roche | Radioligantes rotulados com flúor-18 e carbono-11 para imagiologia por tomografia por emissão de pósitrons (pet) para lrrk2 |
| GB201204985D0 (en) | 2012-03-21 | 2012-05-02 | Genentech Inc | Compounds |
| KR102091895B1 (ko) | 2012-05-03 | 2020-04-14 | 제넨테크, 인크. | 파킨슨병의 치료에 사용하기 위한 lrrk2 조절제로서의 피라졸 아미노피리미딘 유도체 |
| JP6218808B2 (ja) | 2012-05-03 | 2017-10-25 | ジェネンテック， インコーポレイテッド | Ｌｒｒｋ２モジュレ−タ−としてのピラゾ−ルアミノピリミジン誘導体 |
| MD20140130A2 (ro) * | 2012-06-29 | 2015-04-30 | Pfizer Inc. | 4-(amino-substituite)-7H-pirolo[2,3-d]pirimidine noi ca inhibitori de LRRK2 |
| US9815841B2 (en) | 2014-01-29 | 2017-11-14 | Glaxosmithkline Intellectual Property Development Limited | Compounds |
| PE20161443A1 (es) | 2014-01-29 | 2017-01-06 | Glaxosmithkline Ip Dev Ltd | Compuestos |
-
2015
- 2015-01-28 PE PE2016001250A patent/PE20161443A1/es unknown
- 2015-01-28 SG SG11201605342UA patent/SG11201605342UA/en unknown
- 2015-01-28 JP JP2016549028A patent/JP6422986B2/ja not_active Expired - Fee Related
- 2015-01-28 EP EP15743797.1A patent/EP3099695B1/en active Active
- 2015-01-28 EA EA201691514A patent/EA029774B1/ru not_active IP Right Cessation
- 2015-01-28 MX MX2016009893A patent/MX367370B/es active IP Right Grant
- 2015-01-28 WO PCT/CN2015/000055 patent/WO2015113452A1/en not_active Ceased
- 2015-01-28 UA UAA201609099A patent/UA118369C2/uk unknown
- 2015-01-28 US US15/114,858 patent/US10087186B2/en not_active Expired - Fee Related
- 2015-01-28 CN CN201580006361.XA patent/CN105940004B/zh not_active Expired - Fee Related
- 2015-01-28 AU AU2015210593A patent/AU2015210593A1/en not_active Abandoned
- 2015-01-28 KR KR1020167020367A patent/KR20160106622A/ko not_active Ceased
- 2015-01-28 CR CR20160348A patent/CR20160348A/es unknown
- 2015-01-28 MA MA39219A patent/MA39219B1/fr unknown
- 2015-01-28 ES ES15743797T patent/ES2802174T3/es active Active
- 2015-01-28 CA CA2937431A patent/CA2937431A1/en not_active Abandoned
-
2016
- 2016-06-30 PH PH12016501307A patent/PH12016501307A1/en unknown
- 2016-07-03 IL IL246579A patent/IL246579B/en not_active IP Right Cessation
- 2016-07-26 CL CL2016001895A patent/CL2016001895A1/es unknown
- 2016-07-29 DO DO2016000195A patent/DOP2016000195A/es unknown
-
2018
- 2018-01-12 AU AU2018200277A patent/AU2018200277B2/en not_active Ceased
- 2018-08-02 US US16/052,791 patent/US10618901B2/en not_active Expired - Fee Related
-
2019
- 2019-01-15 DO DO2019000010A patent/DOP2019000010A/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA39219B1 (fr) | Nouveaux composés inhibiteurs de la kinase lrrk2 utilisés pour le traitement du parkinson, de l’alzheimer et de la sclérose latérale amyotrophique | |
| MA43335B1 (fr) | Compositions d'arni de transthyrétine (ttr) et procédés pour les utiliser pour le traitement ou la prévention de maladies associées à ttr | |
| MA52486B1 (fr) | Pyridazinones utilisés en tant qu'inhibiteurs de parp7 | |
| MA46018A (fr) | Activateurs d'édition du génome | |
| MA38284A1 (fr) | Inhibiteurs de la phospholipase associée aux lipoprotéines a2 (lp-pla2) à base de 2,3-dihydro-imidazol[1,2-c]pyrimidin-5(1 h)-one | |
| EA201792047A1 (ru) | Новые соединения | |
| MA41179A (fr) | Composés inhibiteurs de parg | |
| EA202092086A1 (ru) | Ингибиторы аргиназы | |
| MA44948A1 (fr) | Inhibiteurs de bace 1 | |
| MA35246B1 (fr) | 1,3-oxazines en tant qu'inhibiteurs de bace1 et/ou de bace2 | |
| MX383213B (es) | Inhibidores de tirosina-cinasas | |
| PH12016501600A1 (en) | 2-amino-3, 5, 5-trifluoro-3, 4, 5, 6-tetrahydropyridines as bace1 inhibitors for treatment of alzheimer's disease | |
| PH12017500841A1 (en) | 2-amino-6-(difluoromethyl)- 5,5-difluoro-6-phenyl-3,4,5,6-tetrahydropyridines as bace1 inhibitors | |
| MA54133A (fr) | Composés d'aminopyrazine diol utilisés comme inhibiteurs de pi3k-y | |
| MA40875A (fr) | 2,4-diamino-quinoléine substituée servant de nouveaux agents anticancéreux | |
| GEP20227442B (en) | Boron containing pde4 inhibitors | |
| MA37763B1 (fr) | Difluoro-hexahydro-cyclopentaoxazinyles et difluoro-hexahydro-benzooxazinyles en tant qu'inhibiteurs de bace1 | |
| EA201890460A1 (ru) | Композиции и способы лечения и предотвращения нейродегенеративных расстройств | |
| MA39533B1 (fr) | Composés, composition pharmaceutique et leur utilisation dans le traitement de maladies neurodégénératives | |
| MA45367B1 (fr) | Inhibiteurs de la tyrosine kinase | |
| WO2015189830A9 (en) | Dual inhibitor compounds for use in the treatment of neurodegenerative disorders and alzheimer's disease | |
| MA39260A1 (fr) | (benzyl-cyano-méthyl)-amides substitués de l'acide 2-aza-bicyclo[2.2.1]heptane-3-carboxylique utilisés comme inhibiteurs de la cathépsine c | |
| EA202190690A1 (ru) | Борсодержащие ингибиторы pde4 | |
| MA47097B1 (fr) | Compositions et procédés pour inhiber l'activité de l'arginase | |
| MA51297B1 (fr) | Quinazolinones en tant qu'inhibiteurs de parp14 |